12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1Jeffrey M. Saland, John C. Lieske, David J. Sas et al.|Journal of the American Society of Nephrology|2020Cited by 4